Back To Old Topics: Merck In Development Deal With Tiny DewPoint, To Seek A Cure For HIV...

It has "been a minute," but we'll drop back into the power alley, to note that while Moderna's vaccine prospects have earned it a buy from Jeffries & Co., and it has risen over nine per cent on the morning (and 230%, on the year) -- there is still a long road ahead, for that company. In similarly complicated, but encouraging news, Merck is excited over DewPoint_x's approach to a potential HIV treatment -- plunking down about a third of a billion dollars to pursue it.

Here's the story from Endpoints News:

. . . .Merck and Dewpoint have agreed on a partnership that will provide the pharma giant with access to the Boston-based biotech’s biomolecular condensate technology in order to develop treatments, and potentially a cure, for the HIV virus. Dewpoint, in turn, will receive up to $305 million in upfront and milestone payments as well as royalties for any approved product. . . .

This has been your small bit of sunshine, piped into the bleak fog of Trumpian disinformation, on all matters bio-science. Smile. . . . [Oh -- and stats are back up, however, sadly. . . I lost all the weekend's data, to a memory hole, in Ireland. Such is life.]

नमस्ते